Treatment for Metastatic Gallbladder Cancer
For metastatic gallbladder cancer, first-line treatment should be gemcitabine plus cisplatin combined with durvalumab (immunotherapy), which has demonstrated superior survival outcomes compared to chemotherapy alone. 1, 2
First-Line Systemic Therapy
Preferred Regimen: Immunotherapy + Chemotherapy
The TOPAZ-1 trial established durvalumab plus gemcitabine-cisplatin as the new standard of care, showing:
- Median OS of 12.9 months vs 11.3 months with chemotherapy alone (HR 0.76, p<0.001) 1
- Improved PFS (HR 0.75, p=0.001) 1
- ORR of 26.7% vs 18.7% 2
Dosing regimen:
- Gemcitabine 1000 mg/m² on days 1 and 8
- Cisplatin 75 mg/m² on day 1-2
- Durvalumab added to this backbone
- Given every 3 weeks 3
Alternative First-Line Options
If cisplatin is contraindicated (renal dysfunction):
For frail patients (PS 2 or significant comorbidities):
- Gemcitabine monotherapy is acceptable 1
Treatment duration: Continue for up to 6 months unless progression or intolerance occurs; insufficient evidence supports continuous treatment beyond 6 months 1
Second-Line Systemic Therapy
When disease progresses on first-line therapy, FOLFOX is the preferred second-line regimen based on the ABC-06 trial 2:
- Median OS 6.2 months vs 5.3 months with best supportive care (HR 0.69, p=0.031) 2
Other Second-Line Options:
- FOLFIRI (median OS 5-6.6 months) 2
- Liposomal irinotecan + fluorouracil + leucovorin (Category 2B) 2
- Regorafenib (Category 2B) 2
- Targeted therapy if actionable molecular alterations identified 2
Special Considerations for Oligometastatic Disease
For highly selected patients with oligometastatic disease (1-3 liver metastases, limited peritoneal deposits, or isolated para-aortic nodes), consider neoadjuvant chemotherapy followed by surgical resection 4:
- Reported 1-year survival: 20-64%
- 3-year survival: 5.7-17%
- 5-year survival: 0-23% 4
Primary tumor resection (PTR) may benefit patients with:
- Isolated liver metastases (HR 0.690, p<0.001) 5
- Isolated distant lymph node metastases (HR 0.498, p<0.001) 5
- One or two metastatic organ sites 5
Avoid extensive hepatic resection or portal vein resection in cholestatic liver due to increased morbidity/mortality 4
Locoregional Therapies
For liver-limited intrahepatic disease:
- Consider arterially-directed therapies in combination with systemic chemotherapy 1
- SBRT may be considered for contraindications to surgery 1
Palliative radiation therapy is appropriate for:
- Symptomatic disease control 2
- Pain management
- Bleeding control
Key Prognostic Factors
Poor prognostic indicators:
- Elevated preoperative CA19-9 and CEA 4
- High platelet-lymphocyte ratio 3
- Elevated alkaline phosphatase 3
- Extra-abdominal disease 3
Monitor CA19-9 levels: Percentage change correlates with PFS 3
Toxicity Management
Expected hematologic toxicities with gemcitabine-cisplatin:
- Neutropenia: 73% any grade, 27% grade 3-4 3
- Anemia: 19% grade 3-4 2
- Consider prophylactic or therapeutic G-CSF 3
With durvalumab addition: Monitor for immune-related adverse events per immunotherapy toxicity guidelines 2
Critical Pitfalls to Avoid
Do not delay molecular profiling - obtain tissue for comprehensive genomic testing at diagnosis to identify targetable alterations for later-line therapy 2
Do not use immunotherapy in patients previously treated with checkpoint inhibitors - lack of data for re-challenge 2
Avoid extensive surgery in patients with elevated bilirubin despite optimal stenting - consider systemic therapy first 1
Do not continue first-line therapy indefinitely - reassess at 6 months for treatment break or switch 1